National Cancer Control Month
April is National Cancer Control Month.
According to CDC, "Cancer control is a journey. It starts with healthy choices like a good diet, vaccines, proper sun protection, and cancer screening—all things that can help make it less likely you will get some kinds of cancer. If you do get cancer, the path shifts to helping you find the best treatment, and then finding support through the rest of your life as a cancer survivor."
Global Academy for Women's Health and BioSciCon, Inc. with their dedicated medical doctors, scientist and educators are working tirelessly and passionately to contribute to the cervical cancer control in the world. This grave, deadly disease is completely preventable and curable IF detected on time by screening. Unfortunately more than 300,000 women die per year from this preventable disease in the 21st Century. Most of them live in the developing countries, where screening is available to only less than 20% of women at risk. There are countries in Africa that the percentage of women who have preventive screening is less than 5% (Uganda). So, almost all women getting cervical cancer (cc) are destined to die, instead, after small early intervention, to continue full productive life. These are somebody's mothers spouses sisters, daughters who die unnecessarily, leaving the whole family devastated.
Why is this happening? In spite of money invested by governments, industry - multi-billion corporations and NGO's, and in spite of the awareness about the danger from cervical cancer, the situation has not been significantly improved until now. There is still 10% increase in mortality. Even in the US, the perfect example of successful prevention with Pap test, most recently cc started to increase among minority populations. WHO is searching for new strategies and new models to fight cc.
Based on analysis of the situation in 57 counties in the world, more than 2/3 of the world population, understanding the real barriers of cc prevention (screening), we describe the new strategy how to fight the challenge of increasing trend of cc. We develop a new strategy and the new tools to enable this strategy. The platform technology includes new biomarkers (Medyko), intensive use of IT technology, particularly image information exchange of files and protocols for global networking, to achieve fast, accurate and low-cost diagnosis via mobile and Internet connection between scattered POCs and medical centers and with a protocol to enable turn-around of data within hours and timely intervention-removal of suspicious lesions that can develop into cc. The MarkPap technology, which is biomarker-based and IT (wired and mobile enabled) is fast, accurate and affordable, infrastructure-independent, accessible, and culture sensitive platform. As such it is aimed for mass cervical cancer screening worldwide.
Since outreach for screening is very important part of the strategy, a Self-Sampling Kit is made available for women to take a sample at home and send it to the POC. This enable woman living in rural areas, far from medical institutions of any kind, to participate in screening, and for those who, because of tradition/religious issues, are not allowed to visit gynecologist. The program is aimed to start in parallel developing local infrastructure enabling sustainability of the new developments. This is exactly according to the recommendations of WHO and Dr.Tedros Adhanom Ghebreyesus, Director General who is acquainted with our work and supports our initiative.
The MarkPap® platform technology is known in India. It has been tested at AIIMS, All Indian Institute for Medical Sciences in New Delhi. Joint papers are published in Indian prestigious journals and the result presented on International meetings. Also, it has been applied at four major medical schools in India where Prof Markovic mentored faculties for their doctorate theses. Indian scientists cite the MarkPap technology as "the future of cervical cancer screening." Currently, there are more than 70,000 deaths from cervical cancer in India. Only less than 20% women get screening. 280 million women are left behind. Collaboration continues.
The MarkPap® patented platform technology (1995) is now widely practiced in China, but under "different names": NewMarkPap, NM Pap, FSC-811. Our Chinese "colleagues" are describing this technology as "innovative technology for the benefit of mankind".
We are now starting to launch the technology In Africa. Cervical cancer is number is the main cause of death from malignant diseases in women.
Our experience is summarized in the Second updated and extended edition of the book "What very woman should know about cervical cancer", published by Springer in 2017. The book is distributed worldwide by Springer and its associates.
This is a monograph-type text book with more than 500 pages, plenty of illustrations, explanation and guidances for professional and non-professional audiences. For professionals, the book provides analysis of current needs and demands (Ch.5), a proposal for a new strategy on how to fight cc (Ch.6), and the new tools to enable this strategy Ch.7): http://www.springer.com/biomed/cancer/book/978-1-4020-6936-9.
Our book is also aimed for public audience, for women to be their companion when they are sick and afraid where to go and seek help, and when they are healthy how to stay healthy (health diet, stress release strategies, etc).
The book is also available on www.amazon.com in electronic version and individual chapters can be downloaded.
It seems that the momentum is coming now. Governments in some developing countries already started to include cervical cancer screening in the yearly women's check up. The WHO is searching for new approaches suggesting new technologies to be made sustainable in those countries. Our book is just on time.
Today, there are 2.4 billion women at risk from cervical cancer who need help. Huge space for tremendous social impact and financial benefit. Making money doing good is the motto in our Consortium of social entrepreneurial companies and a non-profit organization.
Everybody is welcome.
We are trying to develop alliances, strategic partnerships to continue our efforts. Donations are appreciated. Investors are welcome (equity investment, licensing, royalty).
Drs. Olivera & Nenad Markovic legacy continues.
Updated BioSciCon, Inc. Flyer
||Please click the image
to view the flyer.
During the the month of February, when BioSciCon and Global Academy for Women's Health celebrate the National Cancer Prevention Month, we are notified about the acceptance of our presentation at the Experimental Biology 2018 FASEB Meeting entitled "Is HPV Vaccination Secure Protection of Women Without or With Cytological Cancer Screening".
For the second time, BioSciCon, Inc. and Dr. Olivera Markovic were announced winners for the Corporate Vision Magazine Business Woman Awards (2017)
Discussing the awards, Rachel Devonport, Awards Coordinator, commented: "Women represent around half of the global workforce and are a key contributor to the corporate world; despite this, these contributions are often overlooked. As such it is my privilege to showcase the very best women in business across the corporate landscape, and I would like to offer them my congratulations as well as wish them the best of luck as they look to the future."
Awards and Recognitions
Dr. Olivera Markovic was nominated to receive Business Woman of the Year Award 2017
Hosted by Corporate Vision Magazine. "Across the globe, within a vast number of sectors, women continue to go above and beyond to establish themselves as being a significant part of the business world. From healthcare to pharmaceuticals... these awards are purely based upon merit.."
Dr. Olivera Markovic has been selected for 2017 Marquis Lifetime Achievement Award
This award came after a decade of multiple bibliographic citations of Dr. Markovic's work in several editions of Marquis Who is Who.
"We are pleased to announce that Marquis Who's Who has selected you for our official 2017 Albert Nelson Marquis Lifetime Achievement Award. You have been selected to receive this prestigious award as a result of your hard work and dedication to your profession. Congratulations!"
BioSciCon, Inc. has been selected for the 2017 Best of Rockville Award for Biotechnology Research by the Rockville Business Recognition Award Program
"Welcome to the Rockville Business Hall of Fame! BioSciCon, Inc. is among a very small group of companies that have won the Best of Rockville Award for eight consecutive years. This distinction has qualified BioSciCon, Inc. for the 2017 Rockville Business Hall of Fame."
Drs. Olivera and Nenad Markovic contributed to the Experimental Biology National Meeting, EB Chicago, 2017 with a report on Cervical Cancer and HPV: Dilemmas and Resolution via Biomarkers. See Reference #60.
|At the beginning of the Cervical Cancer Awareness Month, we are happy to announce that the second, updated and extended edition of our book "What every woman should know about cervical cancer" was published by Springer. More...
2016 Awards and Recognitions for BioSciCon, Inc.
- NATIONWIDE (DOMESTIC)
We announce with pride that Dr. Olivera Markovic and BioSciCon, Inc. were awarded 2016 Corporate America Elite Award, New York:
Best Woman-Owned Biotechnology Company - Mid-Atlantic.
"The 2016 American Businesswoman Elite Awards are designed to place strong headed women in the spotlight and to give recognition to those most deserving. We have searched the country for strong headed women who continue to shatter glass ceilings on a daily basis and become a significant part of the business world, we feel those individuals deserve to be recognized, and awarded, for their continuous hard work and talents."
Jazmin Collins, Awards Co-ordinator, expressed her pride in the award winners: "Women play a significant part in the corporate market, and as such it is a great honor to be able to turn the spotlight on our amazing winners and showcase their talent and dedication. I would like to wish them the very best of fortunes going forward."
We are also honored to receive Businesswoman Awards 2016 by Corporate Vision Magazine, England
Dr. Olivera Markovic and BioSciCon, Inc. were awarded Best Woman-Owned Biomedical Science Consultants-Maryland.
"Corporate Vision is dedicated to working around the clock to shine a spotlight on the brightest, best performing and most deserving companies and individuals from around the business world.We’re fiercely passionate about recognizing outstanding achievement, game-changing innovation and stellar performance, and all of our awards are carefully tailored to provide detailed and in-depth analysis of the very best each market, industry, sector and region has to offer.We take choosing our winners very seriously and every single one is chosen on merit. As we said, we’re only interested in recognizing the very best so, no matter how big a business is, nobody can buy their way to success ..."
- LOCAL RECOGNITION
BioSciCon, Inc. has been selected for the 2016 Rockville Business Hall of Fame by Rockville Award Program.
"BioSciCon, Inc. is among a very small group of companies that have won the Best of Rockville Award for seven consecutive years in the Biotechnology Research category. This distinction has qualified BioSciCon, Inc. for the 2016 Rockville Business Hall of Fame. To commemorate your inclusion in this elite group an exclusive Hall of Fame Award, available only to Hall of Fame inductees, has been created...These exceptional companies help make Rockville area a great place..."
Labroots Virtual Meetings
Drs. Olivera and Nenad Markovic participated in two recent Labroots Virtual Meetings:
- Could we treat patients with cancer, not cancer with patients. Labroots Cancer Research and Oncology Virtual Meeting, October 5-6, 2016.
See the Abstract, one-page poster and the video "Kinetics of nanoparticles accumulation visualizing potential biomarkers" in Reference #57 (References on this web site)
- POC's past, present and future. IT empowering POC's. A need to equal health care for all. Labroots Clinical Diagnostic and Research Virtual Meeting, Nov 2-3, 2016.
See the Abstract and one-page poster in Reference #58.
It is to announce that Dr. Olivera Markovic is elected Adjunct Professor of Biological Sciences at the University of Maryland Baltimore County. She is currently teaching classes in Graduate Master Degree Program in Biotechnology at UMBC, USG. This is the fifth professorship granted to Dr. Markovic, after Medical Faculty, University in Belgrade, former Yugoslavia, Medical College of Pennsylvania/Drexel University in Philadelphia, PA, Georgetown University, in Washington, DC and American University in Washington DC.
A new composite marker for cervical dysplasia
MEDYKO is a new upgraded MarkPap® biomarker. It is an acronym of ME (metabolic biomarker--acid phosphatase), DY (pathocytological signs of dysplasia) and KO (koilocyte sign of HPV disease).
It combines signs of pre-cancerous condition, cancer disease and cancer prognosis; altogether metabolic, pathocytological and HPV diagnostic assay.
MOTHER'S DAY 2016
Message from the President
Mothers of the World, Foundation of the Family and its Guiding Force, our Heroes -- Happy Mother’s Day!
However, sadly, today in the 21st Century, thousands of women still die from preventable diseases. One example is cervical cancer, whichis completely preventable and curable if detected on time, but it is stillone the major women’s killer in the world, particularly in the developing countries. What to do about it, how to help women aroundthe world?
How to prevent it? The answer is: With cervical cancer screening to detect early changes of cervical cells that may develop into cancer and to educate women how to take better care of their health. Unfortunately, after 70 years of Pap test availability, the ultimate goal – to reverse of cervical cancer trends globally – has been achieved partially – in developed countries, only. In most of developing countries, the outreach for preventive cytological screening is less than 10%. Screening for risk factors such as HPV has contributed, but still not sufficiently.
Is global mass cervical cancer screening possible today? Our answeris: YES, but with new tools. With the fast development of IT technology application in medicine (e-Health & M-Health) and diagnosis at distance (telemedicine), with new biomarkers improving the staining procedure of Pap test, this can happen and thousands of Points-of-Care (POC) may become screening units for affordable cost.
BioSciCon’s MarkPap® platform technology belongs to this new generation of Pap tests. A low-trained technician at the POC in the remote sites can process the specimen with customer-friendly MarkPap® Kit, locate suspicious cells highlighted by the biomarker and transmit microscopic images, via MarkPap® Networking System,to experts for instant diagnosis. Home MarkPap® Specimen collection kit will further increase accessibility and make the test culture-sensitive. See www.bioscicon.com.
The whole procedure should be completed while a woman is still on the premises, some smaller intervention can be performed at the POC, or a woman could be timely directed to a health care institution for further treatment (One-Day Pap test).
This biomarker-based, telemedicine-enabled, infrastructure independent, low-cost, simple, affordable, accessible, and culture- sensitive technology combined with wide education of women to increase awareness about prevention, may become a new tool for mass cervical cancer screening, a technology which can bring right care at the right place and at the right time for lower cost.
The MarkPap® technology is already widely implemented in China, with current efforts to be introduced in India. With targeting support, it could be introduced globally and save thousands of women’s lives.
May this Mother’s Day, 2016 be the beginning of the new era and the best greeting for all women in the world.
BioSciCon Introduces the New Proprietary Biomarker
for Mobile Telecytopathology
BioSciCon, Inc. and the Global Academy for Women's Health have submitted an abstract for the 2016 Experimental Biology Annual Meeting in San Diego, CA , where intend to present their new proprietary biomarker for cancer diagnosis via global mobile telecytopathology.
BioSciCon, Inc. has been selected for 2015 American Leadership Award by the American Economic Institute, Washington, DC.
BioSciCon, Inc. receives 2015 Best of Business Award for Rockville
Small Business Community Association recently selected BioSciCon, Inc. to receive 2015 Best of Business Award for Rockville, MD in the Small Business category.
BioSciCon's MarkPap® [CAP-PAP™] Test in India
We have a long-standing collaboration with Indian scientists where the validity of the of the MarkPap test (CAP-PAP test) in detection of abnormal cells on cervical smears has been confirmed. Please see Publications 38, 51.
In the beginning of this year two more scientific papers were published on the subject in India.
1. Prof. Santwani with her team at the Department of Pathology, Shah Medical College, Jamnagar and Punjab Institute of Medical Sciences, published a paper "Study of CAP-PAP versus conventional Pap in suspicious cervical lesions" using MarkPap Kit with Combo Control Slides. The paper appeared in Int J Res Med 2015;4(1)102-108, concluding that the CAP PAP test could be the future of of cervical cancer screening. Click here to see the article
2. Prof. Nenad Markovic supported a doctoral candidate, Dr. Niranjan J, at the Videhu Institute of Medical Sciences in Bangalore, who performed a clinical trial, according to the design provided, confirming the value of CAP-PAP test and published the results in J Evidence Based Med&Healthcare, 2015; 2(6),714-23, 2015, "Cervical Acid Phosphatase; Evaluation as an adjuvant to papanicolaou smear screening in cervical cancer detection. Click here to see the article
India is a country with 70,000 deaths from cervical cancer per year, and below 10% outreach for the prevention from this disease. Out of 300,000M women at risk only 20M women are protected with preventive cancer screening. Cervical cancer is preventable and curable disease, IF detected on time.
But, new strategy is needed.
On June 11, 2015, Drs Olivera and Nenad Markovic met officially with Minister Counselor for Science and Technology Mr.Tarun Mohandra and Attache Mr. Kumar at the Indian Embassy in Washington, DC. The new Strategy for Fighting Cervical Cancer in India with MarkPap technology tools was presented and discussed. The Strategy has been forwarded to the Indian Ministry of Health.
Our book "What every woman should know about cervical cancer'( Springer, 2008) is popular in India. Recently, two Indian distributors joined the list: Delhi Book Store and Meltek Books.
BioSciCon's MarkPap® Images in China
Original, copyrighted image of a specimen processed with MarkPap® Test, presented on BioSciCon's Gallery page, are plagiarized and published without permission at the website of the Chinese Anhui Science and Technology Co.
MarkPap® in P.R. China
CAP PAP Test, USPTO #6,143,512 (issued in year 2000), MarkPap®, BioSciCon, Inc, USA is gaining popularity in China. It is sold under different names: NewMark-PAP, NM-PAP from Anhui Science and Technology Co., Ltd and FSC-811 from Anyon Biopharmaceuticals, Ltd, both from Hefei, Anhui Province, PR China.
Citation from www.ahnmst.com
"Abnormal cervical squamous cell early screening kit" to detect chemical and enzyme modified Pap staining of cervical squamous cell early lesions improve the readability of abnormal cells, high sensitivity, shortened reading sheet time, low cost, which is very suitable for large-scale screening of cervical cancer, is suitable for use at all levels of medical institutions. "Innovative technology for the benefit of mankind."
BioSciCon is now offering two MarkPap(r) Technology related new products for licensing/sale. Both are in patent pending phase.
1. BioSciCon Smartphone-microscopic Universal Adapter for Telemedicine
2. MarkPap(r) Self-Collecting vaginal/oral specimens Kit(tm) and Test for cancer screening
Please visit our Licensing Page for more information.
BioSciCon, Inc. and its principals have been recognized, endorsed and selected as award recipient by business organizations, associations, media, bibliographical collections, etc. BioSciCon, acknowledges these awards and is honored by the recognitions.
Marquis Who's Who Publication Board recognized and certified Dr. Olivera Markovic for the 15-th jubilant year of being a subject of bibliographical record series of Marquis Who's Who. "Inclusion in which is limited to those individuals who have demonstrated outstanding achievements in their own fields of endeavor and who have, thereby, contributed significantly to the betterment of the contemporary society" (Plaque citation).
The 2013 Best of Rockville Award in the Biotechnology Research Category came to BioSciCon, Inc. from the US Commerce Association, given by the Rockville Award Program. According to the 2013 Rockville Award Program Press Release, "The Rockville Award Program was established to recognize the best of local businesses in the community. . . those companies that have shown the ability to use their best practices and programs to generate competitive advantage and long-term value."
In 2014 BioSciCon has qualified and is nominated for 2014 Rockville Business Hall of Fame.
Please view an insert from the video, presented at the NIH Single Cell Analysis Investigators Conference in April 2014, Bethesda MD.
To read more, click here.
The participation of BioSciCon and the Global Academy for Women's Health on the January 2014 National Conference on Cancer Detection, Diagnosis and Treatment Technologies for Global Health, appeared in Hopkins News, March 2014.
Click here to read the article.
In February 2014 led by BioSciCon, Inc and Global Academy for Women's Health, and with participation of companies from LMIC counties, a project Proposal entitled Wireless Cervical Cancer Screening in Low and Medium Income Counties was submitted to the National Institutes of Health. Click here to read the Narrative of the Proposal.
MarkPap India, LLC, a member of the BioSciCon Consortium, continued with implementation of the Strategy for Fighting Cervical Cancer in India, with simplified, affordable, telemedicine-empowered MarkPap® technology that can bring cervical cancer prevention in rural India, at the BoP, where it is most needed. Unfortunately, at present - in the 21st century - more than 70,000 women a year die in India from preventable cervical cancer.
Please visit our MarkPap India, LLC GUST web site.
In January 2014, led by BioSciCon, Inc and MarkPap India, LLC, sponsored by the Global Academy for Women's Health, project proposal entitled A Comprehensive Information Technology Healthcare Center for Cancer Screening in India was submitted to NIH. Twenty organizations from the US and India are committed to participate in this project. Please click here to read the Narrative of the Proposal.
Global Academy for Women’s Health and BioSciCon participated in the 2014 NIH organized National Conference on Cancer Detection, Diagnosis and Treatment Technologies for Global Health in Bethesda, MD.
The Global Academy presented a review: ”Meeting WHO Recommendations for cervical cancer screening in developing countries.” The presentation was enriched with long experience the authors have gained working with Indian partners in India. Data presented are in support of the concept that the high tech medical devices could always be simplified to meet more limited requirements. One of the solutions to this task is using biomarkers for specific diseases and navigating all consequent procedures and tools through the scope of the selective biomarker.
According to WHO, Pap test remains the best cervical cancer preventive test. However, its classic version cannot be directly applied in the developing world primarily because of the cost and lack of infrastructure. Fortunately, the new biomarker-based Pap test, MarkPap technology products and services which are empowered with telemedicine for distant reading may provide a low-cost, simple, infrastructure independent, accessible, equitable and culture-sensitive opportunity to implement cytological cervical cancer screening all over the world, particularly in the developing world, where it is most needed (www.bioscicon.com).
In the subsequent discussion, Dr. Olivera Markovic emphasized, based on experiences in China and India, that the biggest barrier is not the cost, but lack of infrastructure at the Point-of-Care (e.g., qualified pathologist, trained technicians), which is most difficult to overcome and needs decades to be developed. Here, telemedicine, telecytopathology providing diagnosis on distance, is the method of choice. Particularly, mobile cell phone transmission of microscopic images from the Point-of-Care to the specialist. The whole procedure may take just few hours, and women could get diagnosis and initial treatment within one single day, while still on the premises.
The new ideas attracted a particular interest in the audience, which expressed interest for more information and for guidance on how to use these technological inventions in their environment.
BioSciCon’s had a technology video presentation, a slide show on ”Changing bioactivity of live cancer cell in vitro’” Drs. Markovic revived their single cell analysis technology for monitoring, recording and measuring the kinetics of enzyme activity in a single cell. The concept and model of this technology was developed many years ago, while they were working at NiH, using expensive microscopes and image analyzers. It is now simplified to make it available for researchers with lower resources. Having a possibility to measure the kinetics of intracellular enzyme activity provides a new chemo-sensitivity testing method, which may be used for screening many small molecules for their bioactive properties in search for new anticancer therapeutics.
Global Academy for Women Health and BioSciCon, together with collaborators from the US and India, submitted a grant proposal to NIH, entitled ” A comprehensive IT Telehealth Center for Cervical Cancer Screening in India”. This development, if supported, will open a prospective to screening, diagnosis and treatment of Indian women the same day they visit a Point-of-Care.
Due to popular demand, BioSciCon has upgraded the Consulting Page. Please visit www.bioscicon.com/consulting.html.
The Global Academy for Women's Health, a non-profit affiliate of BioSciCon, Inc., acknowledges the contribution from Ms. Farkhondeh (Ferry) Sadeghi with her beautiful paintings. Ms Sadeghi is pharmacist, philanthropist and one of the most respected and active artists in the Washington Metropolitan Art Society. Her paintings are on display in the Offices of the Global Academy for Women's Health at the Johns Hopkins University, Montgomery County Campus, Rockville, MD. The photo displays her most recent gift to the Academy.
Pap Smear Test Can Be Made Available and Accessible to Women World-Wide.
It has been tested and repeatedly confirmed during BioSciCon's R&D of the proprietary platform technology under the brand name MarkPap®, which is biomarker-based and telemedicine-empowered. The products in the production pipeline are designed to be low-cost, simple, fast, accurate, accessible, equitable and infrastructure-independent, with selective intended application such as Mass Pap Smear Cervical Cancer Screening World-Wide.
Currently, BioSciCon is offering a set of three products from the MarkPap® pipeline for developing countries, particularly India: MarkPap® Test Reagent Kit (a set of reagents, controls and instructions for simple processing specimens by a low-trained technician at the Point-of-Care). MarkPap® Telemedicine Service (diagnosis at distance) and MarkPap® Self-Collection Home Kit (to allow women to take sample at home and send it to the lab for testing). Practically, it means that a women can take a sample at home and send it to the lab where a low-trained person can process the specimen with the simple Reagent Kit. The same person looks on the slide under the microscope searching for biomarker positive (red flagged) abnormal cells and transmits the images of those microscopic fields with a cell phone to specialists. The result could be obtained back within one hour. If implemented, this is how MarkPap® products could bring Pap test across the globe.
The products are ready for marketing, and sales are contingent to the local (in-country) regulatory requirements.
We were present at the 18th International Congress of Cytology in Paris, where the paper entitled "Evaluation of Cytology Screening Strategies for Cervical Cancer In Resource Poor Setting" was presented. Please see the Reference # 51.
BioSciCon, Inc. supported by the Global Academy for Women's Health is currently developing low-cost, simple devices for early detection of oral cancer. Oral cancer is common cancer and is among major health problems in the developing countries, particularly in India. To read more about this most recent effort, click on this link.
BioSciCon, Inc. and its affiliates is continuing its effort for the development of low-cost, simple medical devices which are infrastructure independent and accessible in low-resource countries. Telemedicine (wired and wireless) provides powerful tools to achieve success. Please click here to read "IT Telehealth Center for Telecytopathology" that appeared in The FASEB Journal 2013, 27:874.20.
The Global Academy for Women's Health has submitted Application to the US Indo Government funding for organizing the Symposium "Strategy for Reversing the Negative Trends of Increasing Prevalence and Mortality of Indian Women from Cervical Cancer." The Symposium is anticipated to be held in 2013 at the Johns Hopkins University, Montgomery County Campus in Rockville, MD. The Proposal for a comprehensive strategy to increase the outreach for preventive screening to 50% during the next 10-12 years is in preparation. It is expected that the negative trends of an increasing morbidity and mortality at the current outreach of 6% will start to decrease when reaching 50% point.
In response to the WHO launched the Non-Communicable Disease Action Plan, BioSciCon's Consortium has concentrated on three topics, which are in our domain:
The Global Academy provides assistance to the Consortium member, MarkPap India, LLC, in the Strategy for Fight Against Cervical Cancer in India (See Brochure-November 2012). BioSciCon has sponsored the development of tools to guide this Strategy.
- Develop scientific strategies for cancer prevention and control.
- Develop standards and tools to guide the planning and implementation of interventions for prevention, early detection, treatment and care.
- Provide technical assistance for rapid, effective transfer of best practice intervention to developing countries.
According to the World Health Organization, carcinoma of oral cavity is the sixth most frequent cancer among males in developing countries. Although it represents 2-4% of the malignancies in the western countries, it is estimated to be as high as up to 40% of male cancers in some areas of India.
Inspired by the Global Academy for Women' Health, the non-profit member of the BioSciCon's Consortium, BioSciCon, Inc., a social enterprise, continues its mission for development simple, low-cost medical devices suitable for the Point-of-Care with minimal infrastructure and and low-trained personnel in rural , low-resource areas in the world. MarkPap(r) proprietary platform technology is a typical example for a biomarker-based, telemedicine empowered, simple, affordable, accessible , infrastructure independent technology for early detection of abnormal cells in cervical specimens.
Recently, another medical device. from the same category, APE-100 was announced by BioSciCon for early detection of abnormal cells from oral cavity. Those patients who do not have access to medical institution can obtain oral specimen at home, using a simple Self-Collection Kit and mail it to the doctor’s office. APE-100 is in R&D phase of development.
MarkPap India, LLC Brochure on the "Fighting Cervical Cancer in India"
Recently, MarkPap India, LLC, the whole seller of BioSciCon's proprietary MarkPap(r) products for India, has completed the package of products and services that can be used to reverse cervical cancer negative trends of increasing prevalence and mortality from cervical cancer in this country. MarkPap India has announced the news in its Brochure that can be retrieved by clicking on the link.
|After feasibility testing, the concept for the Universal Adapter was cleared for patentability and a new patent application was filed with the USPTO. Please see images of the early phase of this development.|
The Global Academy for Women's Health is strongly supporting the development of low-cost, simple medical diagnostic devices that could be used globally to alleviate the disparity in women's healthcare. Wireless health is providing a wide avenue to advance in this field, since 80% of the world's population lives in regions with mobile phone accessibility.
Read more about BioSciCon's efforts, supported by the Global Academy for Women's Health, to advance wireless telecytopathology (wireless transmission of microscopic images) from the Point-of-Care to specialists for instant diagnosis, that appeared in Hopkins News, June 2012.
BioScicon and The Global Academy for Women's Health contributed to FASEB Experimental Biology Annual Meeting, 2012 with the following communications:
Is Mass Cytological Cancer Screening Possible Worldwide?
Universal Adapter for Telecytopathology
The preparation of the Second updated and extended edition of “What Every Woman Should Know about Cervical Cancer" is announced in Hopkins News, February 2012.
The renown international publisher Springer invited Dr. Nenad Markovic and Dr. Olivera Markovic to prepare the second, extended and updated edition of their book “What Every Woman Should know about Cervical Cancer." The first edition was published by Springer in 2008; it is well accepted and is distributed worldwide by Springer, Amazon, and affilited distributors.
BioSciCon, Inc. participated at the 2011 NIH Annual SBIR/STTR Conference, held in June 2011 in Bethesda, MD, with the poster entitled: Capitalization of investing into medical device development on the health market.
BioSciCon Consortium participated at the NIH Conference on Cancer Detection and Diagnostics Technologies for Global Health . Bethesda, MD, August 2011 with the presentation entitled: Low cost medical devices combined with telemedicine reduce health disparities between developed and underdeveloped countries.
BioSciCon Consortium has decided to license some of its MarkPap® pipeline products for global cervical cancer screening. Interested parties, please send inquiries to firstname.lastname@example.org for more details.
Dr. Olivera Markovic, Director of BioSciCon, Inc. provided an interview to the Virginia Telehealth Network on the current progress of telemedicine efforts of BioSciCon's Consortium to bring expert medical healthcare to the remote point-of-care locations in low-resource areas, where it is most needed.
Please visit the Virginia Telehealth Network web site.
BioSciCon Consortium submitted Application for NIH US India Collaborative Program on Low-Cost Medical Devices.
BioSciCon Consortium submitted Application to NIH for SBIR phase-1 Grant.
BioSciCon, Inc. has been selected for the 2010 Best of Rockville Award in the Biological Research category by the US Commerce Association. Click here to read more.
BioSciCon, Inc. is featured at Virginia Telehealth Network Web Site. BioSciCon, Inc is developing IT and Mobile Telehealth Center for Telecytopathology Services in Rockville, MD
MarkPap Pacific, LLC is featured in Washington Post
MarkPap Pacific, LLC and its activities were featured in the Washington Post on December 28, 2010. Click here to read the Washington Post article.
MarkPap Pacific, LLC signs a Trade Agreement with Chinese Partner
MarkPap Pacific LLC, a Company from the BioSciCon Consortium, signed a Trade Agreement with Chinese Partner to bring the MarkPap Test to China market: To sell minimum one million tests per year and to use telemedicine (telecytopathology) services during the next five years.
BioSciCon and its companies on the forefront of mHealth current development
The mHealth denotes delivering health care services using mobile wireless communications that has recently emerged as a new viable option for providing health care in developing countries. The Year 2009 is proclaimed as the Year of mHealth. According to the United Nations Foundation, the mHealth is “a high reach, cost-efficient method for making healthcare more accessible, affordable and effective across the developing world.” Many regions in the world do not have access to the Internet, but 80% of the world’s population lives in regions with mobile phone accessibility. This is a huge market for the new mHealth methods, products and services, and a target for the Global Health Initiative and its followers.
BioSciCon’s Consortium of Companies is on the forefront of mHealth current development. We are developing a platform technology for wireless telecytopathology/telemicroscopy that uses mobile cellphone cameras for capturing microscopic images directly from the microscope in remote locations and wireless transmission of those images to distant centers for evaluation by professionals with or without interceptions of web-based digital-image networking systems. The system provides opportunity for the results to be returned to the end users within hours. We have a patentable discovery that could be a revolutionary solution for improving health service delivery and surveillance in the developing world where it is most needed.
The MarkPap® Wireless Telecytopathology™ is based on our prior experience with our proprietary MarkPap® Digital Telecytopathology™. Application of mobile phones for capturing and transmitting microscopic images directly from the microscope with cellphone camera is not an easy task, but we are aware of the challenges and the Wireless Telecytopathology Team is solving them. Please visit www.bioscicon.com/gallery.html to see the Gallery, the actual images obtained with a cellphone camera, applied for early detection of abnormal cells on cervical smears. The previous Gallery, the MarkPap Gallery, is created with a digital camera and it is possible to compare the quality of images between the two.
mHealth heralds a new era in medical communications and health service delivery and requires capable and well equipped multidisciplinary groups and teams devoting their energy to this task. Then the success is warranted.
BioSciCon, Inc. becomes a Corporate Partner of Johns Hopkins University
BioSciCon, Inc. became officially a Corporate Partner of Johns Hopkins University, Montgomery County Campus in Rockville, MD. " We are extremely pleased to be able to meet the needs of this small R&D company on our campus, said Elaine Amir, Executive Director, Johns Hopkins Montgomery County "We've been long planning to create an incubator or accelerator on our campus, and the addition of BioSciCon to our campus is a first step in doing so". (Hopkins Happenings, July/August Issue, 2009).
BioSciCon's MarkPap® Wireless™ Images for Telehealth
In August 2008, we introduced the MarkPap® Wireless™ technology. The technology is based on using standard microscopes and mobile cell camera phones for capturing and transmission of microscopic images to digital imaging systems in order to enable worldwide telemedical diagnosis of pathological specimens. Below is an example of MarkPap® images collected by (1) mobile cell phone camera and (2) digital camera with software for digital image analysis. It is obvious that these two images are comparable and that the image analysis or medical diagnosis could be performed interchangeably.
Both images are taken from the same cervical specimen, processed with MarkPap® test, where abnormal cells were identified with the red biomarker. Normal cells are blue and do not contain the marker. The marker makes the important difference for identification of the medical condition preexisted in the specimen and visualized by the MarkPap® test. We believe that wireless telecytopathology will make a big advancement in global health (telehealth). Only a microscope and a cell phone will allow transmission of images for evaluation at distant places. BioSciCon is inviting scientists and licensing around the world to join their efforts and bring together this opportunity to the world for saving more human lives.
Attention! MarkPap® Wireless™: Wireless telemedicine for pathology and cytopathology
BioSciCon, Inc. filed a Patent Application with the US Patent and Trademark Office for MarkPap® Wireless. This most recent product of the platform MarkPap® Technology is aimed for wireless transmission of microscopic images from remote parts of the world to a laboratory with professionals for evaluation (telecytopathology). According to most recent estimates, worldwide cell phone usage is expected to reach 3.5 billions connections by the end of this year with a highest annual growth in Asia and Africa. BioSciCon, Inc. continues working tirelessly to fulfill its mission bringing an affordable and accessible cervical cancer screening to all women in the world to save women's lives. To speed up this most recent development, BioSciCon welcomes investments/contributions for co-development of MarkPap® Wireless.
Dr. Nenad Markovic and Dr. Olivera Markovic authored the book "What Every Woman Should Know about Cervical Cancer" that has been published by Springer and will be available for purchasing in July 2008. Please visit Springer Web Site.
This book is intended for wide audience: General public, including healthy women at all ages and their spouses, girls and their parents, women suffering from cervical dysplasia, cervical cancer, their families
and caregivers. It will also well serve students and their instructors at colleges and universities and health professionals involved in women's health.
Recent introduction of HPV vaccines has raised hopes for immunization against cervical cancer and for the first time in the history of humanity for eradication of cervical cancer. The new 'opportunity' has changed many current views on cervical cancer prevention, control, diagnosis and treatment. Many canons and guidelines became subject to review and many revisions are coming. This book is intended to summarize most of these events and to present them in a language understandable for general public. We expect the book will bring all readers the rationale for optimism and will provide guidelines as how to gain knowledge and skills for critical thinking and making educated decision when it will be necessary in their lives.
BioSciCon Team for Telecytopathology participated at BIO 2008 International Convention. San Diego, California, June 2008 with a poster in the Innovative Corridor. The title of the presentation is A tool for integration of cytology, HPV screening and telecytopathology.
An independent study using MarkPap test in cervical cancer screening has been performed in India by the Department of Pathology and the Department of Obstetrics and Gynecology of the All India Institute for Medical Sciences (AIMS), New Delhi, India The paper is entitled Cervical acid phosphatase detection: A guide to abnormal cells in cytology smear screening for cervical cancer. It is published in Indian Journal of Cytology, 25 (1),1-5, 2008.
The Global Academy for Women's Health Team participated with an abstract entitled Ask for women' opinion first on FASEB Experimental Biology, 2008. Today's Research: Tomorrow's Health. San Diego, California, April 5-9, 2008.
Drs Markovic participated on the 55th Annual Meeting of the American Society of Cytopathology held in Huston on November 2-6, 2007. They presented the results of the application of MarkPap technology and its prospective in telecytopathology.
Please click here to download the abstract. (PDF format)
BioSciCon participated with a poster MarkPap Test and HPV vaccination in the Innovation Corridor at the BIO 2007 International Convention held in Boston, MA May 6-9, 2007.
At the Larta Venture Forum 2007, BioSciCon had a business Power Point Presentation "BioSciCon presents MarkPap Technology" given by Mr.Michael Dailey. The Forum that was held on May 1 and 2, 2007 in San Francisco, CA, is a cumulative event of the NIH Commercialization Assistant Program, where the new achievements and prospective of MarkPap technology and BioSciCon national and global business opportunities for investment were presented.
BioSciCon participated at the Experimental Biology Meeting held in Washington DC, April 18 -May 2, 2007.
Dr. Nenad Markovic presented the concept on cytopathology between art and science, with advantages and problems of color digital imaging and telecytopathology. Dr. Olivera Markovic disclosed the first results of the survey how women feel about getting their samples for Pap test at home, and provided prospective on a Home Pap Test.
During the course of the NIH Commercialization Assistance Program 2006/2007, BioSciCon presented its business opportunity at the Larta NIH-CAP Outcome Workshop, March 26-30 in Washington, DC.
Dr. Olivera Markovic, Founder of BioSciCon was honored among entrepreneurs 2007 on the Women in Bio 5th Annual Dinner,
"Innovation Without Borders" that was held in Washington DC on March 27, 2007.
Local, national and international citations for BioSciCon:
BioSciCon at FITCI
BioSciCon listed as a corporate partner in World Science
Dr. Nenad Markovic presented a poster entitled MarkPap(r) technology, a new business opportunity for the Mid-Atlantic biotechnology in the Innovation Corridor at the Mid-Atlantic 2006 BIO in Washington DC.
BioSciCon, as NIH/SBIR phase 2 grant recipient, was selected by the National Institutes of Health, Bethesda, MD to participate in 2006 NIH Commercialization Assistance Program, to foster commercialization of the MarkPap technology. Larta Institute from Los Angeles, CA was assigned to this program.
Drs. Markovic participated at the Annual Meeting of the American Association for Cancer Research (AACR). They presented the biomarker-based MarkPap Digital technology, which allows the MarkPap test to be performed in a small laboratory by low-trained technician with easy-to-use MarkPap Kit. Guided by marker-positivity, the technician selects suspicious microscopic fields and transmits the images in diagnostic centers for evaluation by professionals. The results could be returned within hours. The MarkPap Digital opens a prospective for cytological screening around the world.
The same prospective for global cervical cancer control with MarkPap technology was presented at the Innovative Corridor, BIO 2006 Convention in Chicago, IL.
Drs. Markovic participated at the Annual Meeting of the American Federation for Clinical Research (AFCR), Clinical Research 2006, held in Washington, DC. They presented their results on the application of the MarkPap test on HPV positive specimens. Since MarkPap could detect HPV infected cells together with cytological signs of abnormality, it was discussed of exploring this test as a potential method for monitoring the success of the HPV vaccination.
At the Clinical Research 2006, Drs. Markovic also announced the prospective of moving Pap test to be performed in doctor's offices, when the new MarkPap Digital will be developed.
Drs. Markovic actively participated on the NIH/NCI organized 4th Early Detection Network Scientific Conference held in Philadelphia. They presented the principle and the pilot results of MarkPap biomarker-based telecytopathology.
From June through December 2005, BioSciCon started systematic research
and development of its second generation product MarkPap® Digital
in collaboration with New Hope Pharmaceuticals, Inc., Gaithersburg, MD;
GT Vision, Inc., Hagerstown, MD and ComputerCraft, Inc., McLean, VA. Because
of the presence of the biomarker (the hallmark of MarkPap technology),
which is amenable for digital photography and image analysis, MarkPap
test is qualified for telecytopathology. This is our new product MarkPap®
Digital, a potential integrated device combining image acquisition, image
delivery and image analysis modules. MarkPap® Digital will provide
an opportunity the slides to be stained in one location and the images
from the microscopic field to be transmitted into a center for evaluation.
This practically means that a general laboratory technician (in a remote
laboratory or a nurse in a doctor’s office) can stain a specimen
using the MarkPap® kit and will look on the specimen under the microscope
searching only for “red” cells (marker positive--abnormal
cells). Then, he/she will capture images with a digital camera (mounted
on the microscope) and will transmit them via Internet to the center with
pathologist/cytotechnologist for evaluation. The result may be sent back
electronically within hours.
The development of another product MarkPap Self, which allows a woman
to take a specimen in the privacy of her home, is also in progress. Please
BioSciCon’ poster, “MarkPap System. Current status and prospective”
was presented at the Annual Meeting of the American Society for Cytopathology
in San Diego, CA in November, 2005
BioSciCon web site is cited at and is linked with the World Science
web site: http://world-science.net/home/links.html
Another Success Story about BioSciCon appeared on the SCORE DC Chapter web
site. Please click here to access this story.
Read more about BioSciCon presentation on the Century Club Breakfast
at the Business Alliance George Masson Press Release of June 9, 2005
Dr. Olivera Markovic and Dr. Nenad Markovic participated in the Convention
BIO 2005, held in Philadelphia, PA . They presented a poster in
the Innovative Corridor with co-authors Dr. Shelly Parr and Dr. Vojislav
Zizic. The abstract "MarkPap® technology for cervical cancer
control" can be found at:
BioSciCon was selected by the Century Club of George Mason University
for a business presentation at the Century Club Grubstake Breakfast.
The presentation took place on June 9 at Hilton, McLean, VA.
Dr. Nenad Markovic presented the Company and its products. The PP
Presentation can be viewed at the Publication
Page (publication # 17)
The PP presentation "MarkPap® test for cervical
cancer screening" by Dr Nenad Markovic, Dr. Olivera Markovic, Dr.
Edward Henderson and the Cervical Cancer Study Group, from ASCO National
Meeting 2005, can be viewed by clicking here-------
On May 18, 2005, BioSciCon, Inc. Rockville, MD, received the
prestigious SCORE "Small Business Client of the Year 2005
award was presented to Dr. Olivera and Dr. Nenad Markovic at the Annual
SCORE Luncheon at the Wyndham Hotel in Washington, DC in the presence
of SCORE Chapter 1 counselors, highest SBA officials and guests. BioSciCon
was awarded in recognition of a highly successful company, and for its
achievements in the development of new products for cervical
cancer screening and prevention that will improve global healthcare and
save women's lives.
BioSciCon is announcing the incorporation of a business development
The mission of MarkPap, LLC is to commercialize the MarkPap® technology
products. The LLC is accepting applications for new members and for the
management team. If interested, please contact us at email@example.com.
More information to follow.
News from BioSciCon Research and Development.
BioSciCon is currently
developing the MarkPap® Digital and the MarkPap® Self
MarkPap® Digital is the MarkPap® test combined with IT technology
into a system for telecytopathology, based upon the biomarker. MarkPap® Digital
is intended for low-resource countries, where a general technician
can locally perform the simple MarkPap® test with the easy-to-use kit, make
images of "marked" microscopic fields, and transmit them via
internet for evaluation. This is a chance for women in remote parts of
the world to have an affordable cervical cancer screening within hours.
is also based on the same competitive advantage: The presence of the biomarker
on abnormal cells. Since the biomarker is a chemical compound
deposited inside the cytoplasm, it is not a subject of deterioration like
cellular integrity/morphology. We have seen retained red biomarker
even in parts of cytoplasm after cell disintegration. This is a basis of
use of MarkPap® test in vaginal specimens of self-obtained material
Test). This test could be particularly important for women who do not have
access to doctor‚s offices, yet to have cervical cancer screening.
believe that MarkPap® technology should revive the cytological approach
to cervical cancer screening and will provide to the rest of the world
the same benefit that Pap test has given to the developed countries.
MarkPap® technology is compatible with other technologies for cervical
We have recently completed three clinical
trials. We compared a combination (marker+Pap) versus Pap alone,
and found that the combination is
superior for detection of true positive/abnormal specimens (up
to 50%), for reduction of false-negatives (more than 50%), and has
specificity with the control Pap test. The presence of the biomarker
reduced the screening time from 6 min to 3 min per slide. A total
of 2,000 subject/specimens were analyzed by subgroups including:
low- risk general population, high-risk population, Pap smear control
for MarkPap® smears, and ThinPrep Pap test control for liquid-based
We are proud to announce the development of two new Research Sites in Los
Angeles, CA, US. BioSciCon is also developing two new International Research
Sites in New Delhi, India and in Belgrade, Serbia and Montenegro. More information
BioSciCon started exploring equity investment options with local angels
and VCs in order to secure financing for the regulatory study required from
FDA approval for the US market, and the commercialization of the technology.
For more information please contact us at firstname.lastname@example.org, or call 1-301-610-9130.
BioSciCon is finalizing phase II/III clinical laboratory trials
of the MarkPap® Test.
We are currently searching for funding partnership (with individuals or other
enterprises) that will assist us in bringing the new product to market.
A paper by Markovic O, Markovic N, and BioSciCon's Cervical Cancer Study
Group: Cervical acid phosphatase: A biomarker of cervical dysplasia and
potential surrogate endpoint for colposcopy appeared in Disease Markers 19(6), 279-286,
2003/2004. The abstract and the full text are available at:
and STTR Success Story for BioSciCon, Inc.
Markovic N., Markovic, O. Markovic, J. Sundeen, W. Smith Jr., Markovic
S., BioSciCon Cervical Cancer Research Group*: Pap test and new
biomarker-based technology for enhancing visibility of abnormal cells. 40th American
Society for Clinical Oncology Annual Meeting, ASCO 2004, New Orleans,
Louisiana. June 2004. J Clin Oncol, 22,9561,2004 www.asco.org/ac/1,1003,_12-002636-00_18-0026-00_19-003023,00.asp
Nenad and Olivera Markovic participated in the 3rd Annual Early Detection
Research Workshop (EDRN) organized from NCI, NIH in Bethesda,
MD. They presented the development of MarkPap® Technology: From
idea to commercial products. A biomarker-based, in vitro diagnostic
device with potentials for cervical cancer screening. Book of Abstracts
Drs. Olivera and Nenad Markovic participated in the 6th
Annual SBIR/STTR Conference (June 23-24, 2004), organized by NIH in
Bethesda, MD. They
presented, as NIH SBIR 2nd phase awardees, their translational research
entitled MarkPap® Technology for cervical cancer screening. Abstract
Book p.7, 2004.
Dr. Lewis Townsend, President Contemporary Women's Health Associates,
Bethesda MD and Drs. Olivera and Nenad Markovic attended the 52nd Annual
Clinical Meeting of the American College of Obstetricians and Gynecologists
in Philadelphia, PA. They presented the results on MarkPap® test
reduces false-negative rates of cervical cancer screening. Townsend L, Markovic
O, Markovic N, BioSciCon Cervical Cancer Study Group*, Obstetrics and
Gynecology, Suppl. 103, (4), 81S,2004.
*BioSciCon Cervical Cancer Study
Group: Parr Shelley, MD., Ross Alan, MD., Sundeen James, MD., Rosser
Rufus, MD., Gould Jed MD., Posarac
Vladan, MD., Mrs. Linda Townsend.
Dr. James Sundeen, President Diagnostic Pathology Services, Clarksburg,
MD and Medical Director Department of Pathology Prince George Hospital,
Cheverly, MD attended the American Federation for Medical Research
Clinical Research Meeting in Chicago, IL. He presented the results
on Cervical Acid Phosphatase and PreservCyt®. Markovic N, Markovic
O, Sundeen J, Smith W.Jr: Inv Medicine 52, Suppl 2,80,2004.
and Nenad Markovic and Dr. Christopher Kemp, President, Kemp Technologies,
Frederick, MD, attended the Experimental Biology
Meeting 2004 in Washington, DC. They presented the results on: Could
the enzyme-enhanced Pap test be automated? Markovic O, Markovic N,
Kemp C: The FACEB J., Experimental Biology 2004, Abstracts Part 1,
Another poster, A cytoplasmic biomarker for liquid-based Pap was presented on the same meeting. Markovic O, Markovic N, Sundeen
Smith W. Jr:
The FACEB J. Experimental Biology 2004, Abstracts Part 1, A200.
Dr. William Smith, Director, Department of Pathology, Suburban Hospital,
Bethesda, MD attended the 2004 Biennial Meeting of the American Society
for Colposcopy and Cervical Pathology held in Disney's Contemporary
Resort, FL, March 2004. He presented the MarkPap® System for cervical
cancer screening. Smith W Jr, Markovic N, Markovic O, Kumar A, Bermeyo,
Mollish P, late Morris M: ASCCP 2004 Biennial Meeting. Book of Abstracts,
Dr. Olivera Markovic attended the Symposium on Predictive Oncology & Intervention
Strategies in Nice, France, February 7-10, 2004. She presented the
following scientific communications:
Enhancing Pap test with a new
biological marker of cervical dysplasia
MarkPap® Kit for cervical
MarkPap® Test applied on specimens from solution
Markovic O, Markovic N: Cancer Detection and Prevention, 2004 Symposium
Volume, S-53(21), S-149(318,319). See also
Cervical acid phosphatase: A new biomarker of cervical dysplasia appeared
in Arch Oncol 11,243-247,2003. Authors Dr. Olivera Markovic and Dr.
Nenad Markovic, with the members of the BioSciCon Cervical Cancer Study
Group: Dr. James Sundeen, Dr. William Smith, Dr. Shelley Parr, Dr.
Lewis Townsend, Dr. Allan Ross, Dr Rufus Rosser, and Dr. Jed Gould.
|Forward Looking Statement
Except for historical information provided herein these press releases may contain information and statements of a forward-looking nature concerning the future performance of the Company.
These statements are based on suppositions and uncertainties as well as on management's best possible evaluation of future events. As a result, readers are advised that actual results may differ from expected results.